<Record>
<Term>Zileuton</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<SemanticType>Organic Chemical</SemanticType>
<ParentTerm>Lipooxygenase Inhibitor</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Enzyme Inhibitor/Lipooxygenase Inhibitor/Zileuton</ClassificationPath>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Enzyme Inhibitor</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Lipooxygenase Inhibitor</BroaderTerm>
<BroaderTerm>Zileuton</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Zyflo cr</Synonym>
<Synonym>Zyflo</Synonym>
<Synonym>(+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea</Synonym>
<Synonym>Zileuton</Synonym>
<Synonym>ZILEUTON</Synonym>
<Synonym>N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea</Synonym>
<Description>A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)</Description>
<Source>FDA Registry</Source>
<Source>NCI Thesaurus</Source>
</Record>
